Luvox CR is now the only once-daily extended release formulation of fluvoxamine available.
The mechanism of fluvoxamine maleate is presumed to be linked to its specific serotonin reuptake inhibition.
Because of fluvoxamine maleaate’s relatively short Half-life of 15 hours, LUVOX® CR capsules were created as the only once-a-day extended release formulation of fluvoxamine.
Luvox CR uses SODAS technology, or the Spheroidal Drug Absorption System, a registered trademark of Elan Pharma International Limited. Each capsule contains consistent combination of immediate and extended release drug delivery beads.
Following ingestion, immediate release beads in the stomach allow for rapid absorption while reducing the peak plasma concentrations associated with immediate release fluvoxamine. Lowering the peak plasma levels may reduce the severity of certain side effects.
Extended release beads desolving in the intestinal lining provide a second release of fluvoxamine maleate which extends the duration of action by keeping patients above the minimum therapeutic window longer than an immediate release treatment.
In in vitro studies of fluvoxamine maleate had no significant affinity for histaminergic, alpha or beta adrenergic, muscarinic, or dopaminergic receptors. Antagonism of some of these receptors is thought to be associated with various sedative, cardiovascular, anticholinergic, and extrapyramidal effects of some psychotropic drugs.
With SODAS Technology, Luvox CR is now the only once daily fluvoxamine maleate regimen with a starting dose of 100mgs and pivotal clinical trial doses higher than 270mgs
